Lisinopril: dose-peak effect relationship in essential hypertension

Br J Clin Pharmacol. 1988 May;25(5):533-8. doi: 10.1111/j.1365-2125.1988.tb03342.x.

Abstract

1. The dose-peak effect relationship of lisinopril was evaluated in a double-blind, parallel study in 83 patients with mild to moderate essential hypertension (supine diastolic blood pressure = 95-115 mm Hg). 2. After a 4 week placebo washout, patients were randomly assigned to one of four treatments: lisinopril 2.5, 10, 20 or 80 mg day-1 for 1 week. 3. Lisinopril 10 and 20 mg day-1 produced similar peak antihypertensive effects which were greater than that produced by 2.5 mg day-1, but less than that of 80 mg day-1. If the incidence of first-dose symptomatic hypotension is related to the peak effect, then an initial lisinopril dose of 20 mg should not pose any greater risk than a 10 mg dose. 4. The magnitude of antihypertensive response at 24 h postdrug appeared to be dose related across the 2.5 to 80 mg day-1 range.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Blood Pressure / drug effects
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Enalapril / administration & dosage
  • Enalapril / adverse effects
  • Enalapril / analogs & derivatives*
  • Enalapril / therapeutic use
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Lisinopril
  • Male
  • Middle Aged
  • Random Allocation

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Enalapril
  • Lisinopril